Preclinical Evaluation of the α-Particle Generator Nuclide 225Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors
Authors:
- 1 June 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (11) , 3555-3561
Abstract
Purpose: Peptide receptor radionuclide therapy (PRRT) using somatostatin analogues labeled with β-particle–emitting isotopes such as 90Y or 177Lu has been a promising treatment strategy for metastasized neuroendocrine tumors. Although remission can be accomplished in a high percentage of neuroendocrine tumors, some tumors do not respond to this treatment. α-Emitting isotopes—such as the 10-day half-life α-emitting generator nuclide Actinum-225 (225Ac)—are characterized by extremely high cytotoxic activity on the cellular level, and may be superior in the treatment of neuroendocrine tumors not responding to PRRT using β-emitting isotopes.Keywords
This publication has 17 references indexed in Scilit:
- Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applicationsAdvanced Drug Delivery Reviews, 2008
- 213Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude miceCancer Science, 2007
- Somatostatin-receptor-targeted α-emitting 213Bi is therapeutically more effective than β−-emitting 177Lu in human pancreatic adenocarcinoma cellsNuclear Medicine and Biology, 2007
- Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumoursActa Oncologica, 2007
- Mitigation of radiation nephropathy after internal α-particle irradiation of kidneysInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- 213Bi-[DOTA0, Tyr3]Octreotide Peptide Receptor Radionuclide Therapy of Pancreatic Tumors in a Preclinical Animal ModelClinical Cancer Research, 2006
- Efforts to Control the Errant Products of a Targeted In vivo GeneratorCancer Research, 2005
- Cancer radioimmunotherapy with alpha-emitting nuclidesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2005
- Tumor Therapy with Targeted Atomic NanogeneratorsScience, 2001
- Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: Evidence for SSTR2 heterogeneityPeptides, 1994